Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

2,898 total articles

Zeta Global: Growth Is Back — But Is the Rally Priced In?

Zeta Global: Growth Is Back — But Is the Rally Priced In?

Zeta Global (ZETA) has re-emerged as a growth story after a series of strong top-line prints and expanding free cash flow. The market has mostly reset expectations from its 2025 slump, yet valuation still implies meaningful future growth. This trade idea outlines a mid-term long with an entry near the current price, a stop below recent intraday low…

Front-Running Copart's Buyback Window: Tactical Long

Front-Running Copart's Buyback Window: Tactical Long

Copart (CPRT) checks the boxes for a tactical long: solid free cash flow ($1.41B), effectively no debt, and a share base that management can meaningfully pare without risking leverage. We recommend buying near $37.56 to play an expected repurchase cycle and earnings re-acceleration over the next 180 trading days.

Navan: A Swing Trade on the IPO Hangover

Navan: A Swing Trade on the IPO Hangover

Navan's share price sits near the low of its first year public, trading at roughly $10 with a $2.46B market cap. Technicals show short-term stabilization and bullish MACD momentum, while headlines about rising sales & marketing spend and pending securities suits keep sentiment weak. This trade idea outlines a mid-term (45 trading days) long with an…

Hims & Hers: Ride the Relief, Not the Euphoria

Hims & Hers: Ride the Relief, Not the Euphoria

HIMS gapped higher after settling with Novo Nordisk and striking a distribution deal for Wegovy/Ozempic; the move removes a headline risk and creates a tactical mid-term buying opportunity. Valuation is reasonable relative to growth expectations but volatility, execution risk on international expansion, and GLP-1 market dynamics argue for a discipl…

Vicor: High-Margin AI Power Play — Buyable Now, Priced for Growth

Vicor: High-Margin AI Power Play — Buyable Now, Priced for Growth

Vicor (VICR) is a niche leader in high-density power modules that has become a direct beneficiary of AI and data-center buildouts. Strong Q3 results, favorable ITC rulings, and an accelerating licensing stream support a bullish case. The shares are expensive on traditional metrics but justify a premium if Vicor hits scale targets; this trade outlin…

Micron's HBM Play: A High-Conviction Long with Defined Risk Controls

Micron's HBM Play: A High-Conviction Long with Defined Risk Controls

Micron is positioned to capture the AI memory squeeze thanks to HBM demand, an oligopolistic supply base and a massive capex program. The stock is expensive by traditional multiples but the growth and cash generation story justifies a targeted long with a disciplined stop. Entry, stop and target included for a 180-trading-day campaign.

Vermilion: A Levered Play on a European Gas Rebound

Vermilion: A Levered Play on a European Gas Rebound

Vermilion Energy (VET) owns meaningful upstream gas exposure in France, Netherlands, Germany and Ireland and is starting 2026 with lower debt, a raised quarterly dividend and bullish technicals. With market cap of $1.75B, a dividend yield north of 3%, and sizable short interest, VET offers an asymmetric trade if European gas prices spike. This idea…

HIMS: Legal Clearance and Distribution Deal Create a Tactical Buy

HIMS: Legal Clearance and Distribution Deal Create a Tactical Buy

Hims & Hers (HIMS) surged after resolving its dispute with Novo Nordisk and securing distribution of GLP-1 products on its platform. The deal removes a major overhang, pairs with a $1.15B Eucalyptus acquisition to accelerate international growth, and leaves the stock trading at a reasonable multiple for a recovery trade. This is a mid-term swing tr…

Buy the Pullback in AngloGold Ashanti - Own the Free Cash Flow Engine

Buy the Pullback in AngloGold Ashanti - Own the Free Cash Flow Engine

AngloGold Ashanti (AU) looks like a high-conviction buy on a pullback. The shares are trading near the 50-day EMA and well below the 52-week high, while the company continues to demonstrate asset monetization, strategic investments, and a cash-generative portfolio. This trade targets a return to the upper-$120s over the next 180 trading days with a…

Euroseas (ESEA): Deep-Value Container Play with Near-Term Catalysts

Euroseas (ESEA): Deep-Value Container Play with Near-Term Catalysts

Euroseas is trading at bargain multiples (P/E 3.3, P/B ~1.0) with a market cap of ~$460M and an upcoming ex-dividend date on 03/10/2026. Recent time charters for fuel-efficient 1,800 TEU feeders at $22k-$24.25k/day and a technically constructive setup support a mid-term long trade. The trade carries cyclical and execution risks; use a clear stop an…

Snowflake: Buying the Pullback to a New Growth Chapter

Snowflake: Buying the Pullback to a New Growth Chapter

Snowflake (SNOW) has pulled back from its 52-week highs but still trades at premium multiples. With a $61.6B market cap, 30% reported revenue growth, and clear AI positioning, the stock offers a tactical long opportunity for investors willing to accept valuation and legal risk. This trade idea lays out entry, stop, targets, catalysts, and the scena…

Tactical Swing: Buy UROY for Royalty Exposure to the Uranium Upswing

Tactical Swing: Buy UROY for Royalty Exposure to the Uranium Upswing

Uranium Royalty Corp. (UROY) offers investors a way to participate in higher uranium prices through a growing royalty portfolio and selective physical holdings. At a market cap of roughly $504.6M and a share price near $3.65, UROY is a leveraged, lower-capex play on the sector. This note lays out a mid-term (45 trading days) swing trade: entry $3.6…

DELIVER Data and Phase-3 Start Put Dyne (DYN) Back on the Biotech Radar

DELIVER Data and Phase-3 Start Put Dyne (DYN) Back on the Biotech Radar

Positive cardiopulmonary results from the DELIVER trial and the initiation of the Phase 3 HARMONIA study for z-basivarsen (DYNE-101) meaningfully de-risk Dyne's clinical story. With shares trading near $17 and market cap around $2.8B, the setup favors a disciplined long swing trade that captures further validation and potential re-rating as late-st…

Tilray Looks Like a Future Winner — For Now Treat It as a Hold

Tilray Looks Like a Future Winner — For Now Treat It as a Hold

Tilray's move into global beverages via the BrewDog asset purchases meaningfully boosts revenue and expands distribution, taking total annualized revenue toward ~$1.2B. Fundamentals and valuation (market cap near $0.8B, P/S ~1, P/B ~0.53) argue the stock is cheap on many metrics, but negative margins, persistent free cash flow losses, and weak tech…

Sea Ltd.: Buy the Post-Earnings Weakness for a 6-Month Recovery Play

Sea Ltd.: Buy the Post-Earnings Weakness for a 6-Month Recovery Play

Sea Limited plunged after Q4 commentary emphasized margin compression and softer Garena bookings despite beats. That sell-off has pushed technicals into oversold territory and trimmed valuation expectations versus the stock's recent highs. This trade idea takes a disciplined long stance: enter after the post-earnings weakness, use a tight structura…